We came across a bullish thesis on Bausch Health Companies Inc. on Countervail Capital’s Substack by Johann Colloredo-Mansfeld. In this article, we will summarize the bulls’ thesis on BHC. Bausch Health Companies Inc.'s share was trading at $7.25 as of September 11th. BHC’s trailing and forward P/E were 27.88 and 1.76 respectively according to Yahoo Finance. 25 Best Work-Life Balance Jobs to Enjoy Life Photographee.eu/Shutterstock.com Bausch Health (BHC), formerly Valeant Pharmaceuticals, is a diversifi ...

公司战略调整 - 公司为提升盈利能力决定分拆糖尿病护理业务单元 该业务是唯一面向消费者的业务且利润率较低 分拆后预计支持盈利改善 [2] - 核心业务保持稳健 作为全球最大医疗器械制造商之一 覆盖广泛治疗领域 持续开发和推出创新产品推动收入及利润稳定增长 [3] 股息表现 - 公司连续48年实现股息增长 距离成为股息之王仅差2年 [4] - 季度股息为每股071美元 股息收益率为298% 数据截至9月18日 [4] 行业地位 - 公司被列入最佳股息股票投资组合名单 [1] - 被认为是2025年股息股票投资组合的重要组成部分 [2]

We recently published 10 Stocks Losing Big Amid Market Boom. Microbot Medical Inc. (NASDAQ:MBOT) is one of the worst performers on Thursday. Microbot extended its losing streak to a fourth consecutive session on Thursday, shedding 6.93 percent to close at $3.09 apiece as investor sentiment was dampened by a potential dilution from a fundraising program that could deliver the company worth $63 million. In a statement earlier this week, Microbot Medical Inc. (NASDAQ:MBOT) said it was able to raise $25.2 mi ...

Key Takeaways SGHT announced a published meta-analysis validating OMNI's long-term safety and efficacy.SGHT's OMNI was shown to reduce IOP and medication use with durable outcomes.SGHT reported that nearly 89% of patients achieved at least 20% IOP reduction at 6, 12 and 24 months.Sight Sciences (SGHT) recently announced the publication of a systematic literature review and meta-analysis in the European Journal of Ophthalmology, highlighting the long-term safety and efficacy of the OMNI Surgical System (OMNI ...

产品发布与定价策略 - 公司推出支持房颤筛查及多项健康指标监测的上臂式电子血压计KSY3610和臂筒式电子血压计KSY8600 [1] - 新品KSY3610系列定价259元起 将高端血压监测技术带入两百元级市场 [1] - 定价策略体现科技普惠理念 可能重塑家用医疗设备市场竞争格局 [1] 技术优势与产品特性 - 产品采用双传感器+人工智能算法捕捉柯氏音变化 测量精准度与水银血压计一致 [2] - 技术对房颤、心律不齐、低血压等特殊人群适用 有效避免漏诊误诊 [2] - 创新整合房颤筛查功能 支持单次测量同时完成血压测量和房颤筛查 [2] - 搭载自研医养大模型AI 用户可通过智能APP获得健康问题专业解答 [2] 市场背景与发展趋势 - 中国加入《关于汞的水俣公约》 要求2026年起全面禁止含汞血压计生产使用 [3] - 血压计行业呈现院内器械家用化、家用器械线上化趋势 [3] - 2022-2025年京东血压计行业复合增速约18.6% [3] - 带房颤筛查和心电监测产品及柯氏音电子血压计产品表现突出 [3] 公司战略与竞争优势 - 通过技术突破和工艺优化实现高功能低价格产品策略 [2] - 构建硬件+软件+服务模式 形成健康领域生态优势 [2] - 将医疗级监测技术下放至消费级市场 通过规模化生产和生态服务价值挖掘构建新盈利模式 [3]

 Toronto, Ontario – TheNewswire - (September 19, 2024) - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce the successful completion of its annual audit under the Medical Device Single Audit Program (MDSAP), ISO 13485 Quality Management System, and EU Medical Device Regulation (MDR) requirements by Notified Body. The audit resulted in zero major nonconformities and confirmed Ventripoint Diagnostics Ltd.’s continued compliance with global quality and ...

It’s an exciting time to be a growth investor despite the current volatility.Thanks to modern brokerages, it’s easier and cheaper than ever to access a wide range of global stocks. With so many options at your fingertips, the possibilities are vast – but so is the noise.The internet is flooded with data, opinions, and analysis, making it difficult to zero in on truly promising growth stocks. Add in the constant barrage of headlines from business news outlets, and it’s easy to feel overwhelmed.That’s why sta ...

MINNEAPOLIS and BRISBANE, Australia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that after convening its Special Meeting of Stockholders (the “Special Meeting”) virtually on Thursday, September 18, 2025, at 5:00 p.m. Central time (being 8:00 a.m. AEST on Friday, Sep ...

U.S. medical device maker GE Healthcare is working with advisers to explore options for its China unit including an outright sale, a person with knowledge of the discussions said on Friday. ...

市场规模与增长 - 全球阵发性室上性心动过速(PSVT)市场2024年估值为13.5亿美元 预计2032年将达到21.2亿美元 2025至2032年复合年增长率为5.8% [1] 市场驱动因素 - 全球心血管疾病负担增加和人口老龄化趋势推高心律失常患者数量 [5][12][14][19] - 诊断和治疗技术进步 包括高分辨率3D电解剖标测系统和新型消融能量源(如脉冲场消融)的开发 [6][15][18] - 微创导管消融手术因其高成功率和治愈潜力被越来越多地采用 [13][16][22][29] - 患者和医疗提供者对PSVT的认识提高 推动更早诊断和干预 [5][19][20] 技术趋势与创新 - 人工智能和机器学习应用于心电图分析 实现前所未有的诊断精度和早期检测 [2][3][4][8][11][15] - 可穿戴和微型植入式心脏监测设备的普及 支持连续远程监测 [3][6][13][15][18] - 机器人辅助导管消融和药物洗脱球囊等先进技术提高治疗精确度和靶向给药 [15][21] - 基因疗法、干细胞研究和生物标志物发现为个性化治疗开辟新途径 [15][21] 治疗方式演变 - 导管消融作为首选治愈性程序 因其高成功率和微创特性而需求增长 [5][13][16][22][29] - 药物治疗向副作用更少的新型抗心律失常药物发展 [8][20] - 非药物干预如迷走神经操作和神经调节技术作为替代治疗方案受到关注 [10][21] - 治疗场所有向门诊和家庭护理模式转变的趋势 强调成本效益和患者便利 [13][17][20] 区域市场动态 - 北美(尤其是美国)因先进医疗基础设施和高医疗支出占据市场主导地位 [24] - 欧洲国家如德国、英国和法国凭借强大的政府支持和研发活动贡献显著份额 [25] - 亚太地区预计增长最快 受改善的医疗基础设施和人口大国需求推动 [26] - 拉丁美洲及中东非洲地区通过医疗旅游投资和现代化医疗设施开发逐步扩大市场 [27][28] 细分市场前景 - 按类型分 房室结折返性心动过速(AVNRT)作为最常见类型驱动持续需求 [10][29] - 诊断领域中 电生理(EP)测试和事件监测因精确数据和连续捕获能力而增长 [10][29] - 治疗领域内 导管消融部门预计将显著扩张 [22][29] - 终端用户方面 心脏病专科诊所和流动手术中心因转向专业化门诊护理而增长 [10][29] 行业竞争格局 - 主要参与者包括辉瑞(Pfizer)、诺华(Novartis)、赛诺菲(Sanofi)、强生(Johnson & Johnson)等制药巨头 [9] - 美敦力(Medtronic)、雅培(Abbott)、波士顿科学(Boston Scientific)等医疗设备公司在技术创新中扮演关键角色 [9][15] - 葛兰素史克(GlaxoSmithKline)和阿斯利康(AstraZeneca)等公司也参与市场竞争 [9]